openPR Logo
Press release

Lymphoblastic Lymphoma Market Trends and Forecast by 2016 - 2024

06-26-2017 03:48 PM CET | Health & Medicine

Press release from: TMR - Healthcare

Lymphoblastic Lymphoma Market Trends and Forecast by 2016 - 2024

Lymphoblastic lymphoma involves both T-lymphocytes and B-lymphocytes, of which 84% to 90% cases of lymphoblastic lymphoma involve T-lymphocytes. Chemotherapy is the preferred choice and first line treatment in cases of lymphoblastic lymphoma, where the regimen is followed for the treatment and includes induction chemotherapy, consolidation chemotherapy, and continuing chemotherapy. Other treatments include radiotherapy which might be given in the brain or spine if lymphoma cells are present or in other areas, stem cell transplantation, and steroids. Lymphoblastic lymphoma is a rare and aggressive form of non-Hodgkin lymphoma; however, it can be cured with 80% to 90% survival rates in children with intensive therapy for early stages (I & II), while 80% survival rates in more advanced stages of lymphoblastic lymphoma (stage III & IV).

Obtain Report Details @
http://www.transparencymarketresearch.com/lymphoblastic-lymphoma-market.html

Lymphoblastic lymphoma is an aggressive form of non-Hodgkin lymphoma; however, it is relatively rare form affecting an estimated 2% patients of all non-Hodgkin lymphoma patients. Lymphoblastic lymphoma primarily affects teenagers or adults in their early 20s, and occurs more frequently in males than females. Lymphoblastic lymphoma arises most commonly from T-cells / t-lymphocytes, and is predominantly a lymph node-based disease, affecting the lymphatic system. The clinical distinction of the diseases - lymphoblastic lymphoma (LBL) and acute lymphoblastic leukemia (ACL) - vary according to different institutions and studies. However, recently, the World Health Organization (WHO) stated that the characteristics of lymphoblastic lymphoma and acute lymphoblastic leukemia are similar at all levels genetically, morphologicallym, and phenotypically as well. Hence, it has unified these diseases as precursors of T-cells / B-cells lymphoblastic lymphoma/leukemia.

Rising incidence combined with increasing prevalence of cancer across the world is the major factor expected to drive the global lymphoblastic lymphoma market during the forecast period from 2016 to 2024. Additionally, increasing prevalence of genetic diseases and technological advancements in the field of diagnostics is expected to augment the global lymphoblastic lymphoma market. According to the American Cancer Society, as on January 1, 2016, there were an estimated 686,390 non-Hodgkin lymphoma cancer survivors in the U.S., out of which around 13,727 patients were lymphoblastic lymphoma survivors. Surveillance studies of the American Cancer Society also indicate that the total number of all types of cancer survivors is expected to reach 20.3 million patients by 2026, out of which people suffering from non-Hodgkin lymphoma is expected to reach 925,150. This increasing incidence and prevalence rate is expected to drive the global lymphoblastic lymphoma market from 2016 to 2024.

In terms of region, the global lymphoblastic lymphoma market is classified into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America dominated the global lymphoblastic lymphoma market in 2015 due to increasing prevalence of cancer especially non-Hodgkin lymphoma, along with advanced diagnostic instruments and technologies, increasing health care expenditure, and rising patient demand for better health care facilities. Increasing focus on targeted drugs for diseases and rising prevalence of cancer is likely to drive the market in Europe. The global lymphoblastic lymphoma market in Asia Pacific is expected to register highest CAGR during the forecast period from 2016 to 2024. Rising genetic diseases and increasing incidence of non-Hodgkin lymphoma in countries in Asia Pacific such as China and India are expected to drive the global lymphoblastic lymphoma market in the region from 2016 to 2024.

Key players in this market are Novartis AG, Sanofi SA, Pfizer, Inc., Bristol-Myers Squibb Company, Jazz Pharmaceuticals plc, AstraZeneca, Eisai, Inc., Amgen, Inc., and BioCryst Pharmaceuticals, Inc. Key players in the research and development are the National Cancer Institute, the University of Texas MD Anderson Cancer Center, the Fred Hutchinson Cancer Research Center, the Memorial Sloan Kettering Cancer Center, St. Jude Children's Research Hospital, and the Johann Wolfgang Goethe University Hospitals, and others.

Fill the form for an exclusive sample of this report @
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2924

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who us e proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Contact

Transparency Market Research
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com
Browse market research blog:
https://tmrresearch.blogspot.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Lymphoblastic Lymphoma Market Trends and Forecast by 2016 - 2024 here

News-ID: 596325 • Views:

More Releases from TMR - Healthcare

Clinical Trial Management System (CTMS) Market : Projection of Each Major Segment over the Forecast Period
Clinical Trial Management System (CTMS) Market : Projection of Each Major Segmen …
With companies long having realized that the best way to remain competitive in the pharmaceutical industry is by ploughing back of profits into R&D projects, the demand for clinical trial management systems is expected to see an uptick. While this will help impel the market greatly in the coming years, what also needs to be taken into consideration that the cost of implementing such a system may deter investment decisions. The
Electronic Health Records Market : Industry Analysis and Detailed Profiles of to …
The global market for electronic health record (EHR) features a largely fragmented vendor landscape, with the presence of a large number of small and large players and the top five companies cumulatively accounting for a nearly 44% of the overall market in 2016. Leading vendors in the global EHR market are adopting inorganic growth strategies such as mergers and acquisitions to expand their reach across high-growth potential regional markets, consolidate
Fuel Oil Market Intelligence Report Offers Growth Prospects
Fuel Oil Market Intelligence Report Offers Growth Prospects
The global transportation industry has been growing at a significant pace since the past decade. Companies operating in the transportation industry are the largest consumers of the fuel oil. Apart from this, fuel oil also finds application in the petrochemical industry and petroleum refineries. The building materials industry is also on the rise since many years. The demand for fuel oil is expected to increase from the building materials industry.
Thermoset Resin Market Global Industry Analysis, Trends and Forecast, 2016 - 2024
Thermoset Resin Market Global Industry Analysis, Trends and Forecast, 2016 - 202 …
The global composite industry has been expanding significantly in terms of production, technological advancements, and developments. Thermoset resin plays a vital role in the composite industry. Thermoset resins are used extensively in the manufacture of composites; these resins are employed in the fabrication of products for end-use industries such as aerospace, automotive, sporting goods, construction, electronics, and wind energy. The thermoset resin market can be segmented into six resin types:

All 5 Releases


More Releases for Lymphoblastic

Acute Lymphoblastic Leukemia Market Size & Growth Analysis Report, 2021-2027
The global acute lymphoblastic leukemia market is growing at a significant CAGR during the forecast period. One of the major factors that are driving the global acute lymphoblastic leukemia market is the growing number of patients of acute lymphoblastic leukemia. According to the Leukemia & Lymphoma Society, approximately every 3 minutes one person in the United States (US) is diagnosed with blood cancer. Further, an estimated combined total of 176,200
Lymphoblastic Lymphoma Therapeutic Market to Witness Robust Expansion by 2025
LP INFORMATION recently released a research report on the Lymphoblastic Lymphoma Therapeutic market analysis, which studies the Lymphoblastic Lymphoma Therapeutic's industry coverage, current market competitive status, and market outlook and forecast by 2025. Global “Lymphoblastic Lymphoma Therapeutic Market 2020-2025” Research Report categorizes the global Lymphoblastic Lymphoma Therapeutic market by key players, product type, applications and regions,etc. The report also covers the latest industry data, key players
Acute Lymphoblastic Leukemia Therapeutics Market - Global Industry Insights, 202 …
Acute lymphoblastic leukemia (ALL) is a type of cancer affecting the bone marrow and blood. The condition is characterized by overproduction of immature white blood cells, also known as lymphoblast. The immature or abnormal cells are unable to function properly and build up around the healthy cells. Patients diagnosed with ALL are highly susceptible to recurrent infections, anemia, bleeding and bruising easily as the bone marrow is unable to form
Lymphoblastic Lymphoma Market : Overview and Analysis
Lymphoblastic lymphoma involves both T-lymphocytes and B-lymphocytes, of which 84% to 90% cases of lymphoblastic lymphoma involve T-lymphocytes. Chemotherapy is the preferred choice and first line treatment in cases of lymphoblastic lymphoma, where the regimen is followed for the treatment and includes induction chemotherapy, consolidation chemotherapy, and continuing chemotherapy. Other treatments include radiotherapy which might be given in the brain or spine if lymphoma cells are present or in other
Lymphoblastic Lymphoma Market: Future market projections for forthcoming years
Lymphoblastic lymphoma is an aggressive form of non-Hodgkin lymphoma; however, it is relatively rare form affecting an estimated 2% patients of all non-Hodgkin lymphoma patients. Lymphoblastic lymphoma primarily affects teenagers or adults in their early 20s, and occurs more frequently in males than females. Lymphoblastic lymphoma arises most commonly from T-cells / t-lymphocytes, and is predominantly a lymph node-based disease, affecting the lymphatic system. The clinical distinction of the diseases
Lymphoblastic Lymphoma Market: Emerging niche segments and regional markets
Lymphoblastic lymphoma is an aggressive form of non-Hodgkin lymphoma; however, it is relatively rare form affecting an estimated 2% patients of all non-Hodgkin lymphoma patients. Lymphoblastic lymphoma primarily affects teenagers or adults in their early 20s, and occurs more frequently in males than females. Lymphoblastic lymphoma arises most commonly from T-cells / t-lymphocytes, and is predominantly a lymph node-based disease, affecting the lymphatic system. The clinical distinction of the diseases